ChemoCentryx, Inc.

(NASDAQ GS: CCXI)

Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of ChemoCentryx, Inc. (“ChemoCentryx”) on behalf of stockholders. A class action complaint has been filed against ChemoCentryx. The complaint alleges that, between November 26, 2019 and May 6, 2021, defendants misrepresented and/or failed to disclose to investors that: (i) the study design of ChemoCentryx’s Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of the drug candidate avacopan and its role in the management of ANCA-associated vasculitis; (ii) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (iii) these issues presented a substantial concern regarding the viability of ChemoCentryx’s new drug application for avacopan for the treatment of ANCA-associated vasculitis; and (iv) as a result, defendants’ public statements were materially false and misleading.

Join This Action

First Name*

Last Name*

Email Address*

Mailing Address*

City*

State/Province*

Zip/Postal Code*

Phone*

Number of Shares Purchased

Date(s) Shares Purchased

Purchase Price Per Share

Number of Shares Sold

Date(s) Shares Sold

Sale Price Per Share

Comments

Alternatively, you may upload your transactions using the upload button below or email them to info@rl-legal.com.

Select files

By signing and clicking the Submit button below, I hereby execute the Retention Agreement and, upon execution of the Retention Agreement by Rigrodsky Law, P.A., retain Rigrodsky Law, P.A. to bring a lawsuit on my behalf pursuant to the terms set forth in the Retention Agreement, which is incorporated herein by reference.*

Draw your signature below using your mouse* [Clear]

Signed pursuant to California Civil Code Section 1633.1, et seq. - and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.

Date of signing: 05/18/2022

X Code

* Indicates a required field.